Short 4-week hepatitis C treatment for early liver disease
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests whether a very short 4-week course of two hepatitis C drugs (sofosbuvir and glecaprevir-pibrentasvir) can cure hepatitis C in people with early-stage liver disease. The goal is to see if a shorter treatment works as well as longer ones.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have chronic hepatitis C (infection for more than 6 months) and have never been treated for it.
- Your liver has minimal to moderate scarring (stage F0 to F2) — not advanced cirrhosis.
- If you have HIV, it must be well-controlled (CD4 count above certain levels and undetectable HIV if on treatment).
- You are not pregnant, breastfeeding, and use effective birth control during and 30 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at hepatitis C treatment for people whose last antiviral medicines did not fully clear the virus. It may help by testing a study drug approach for people in Pakistan who still have active hepatitis C infection.
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
This study aims to make hepatitis C treatment simpler and more accessible for people who inject drugs. If you join, you'll receive care that fits your lifestyle and helps cure hep C.
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
This study tests hepatitis C virus (HCV) treatment using medications called sofosbuvir and velpatasvir, with the goal of curing the infection. If you've been treated before and the virus came back, you may be eligible for retreatment with additional medication.
This study offers a once-daily pill (Epclusa) to treat hepatitis C for people in jail who have never taken HCV medicine before. The goal is to see if starting treatment while incarcerated and continuing after release can cure the infection.
Hear when a new Hepatitis C trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.